Evidence Comparison
Cagrilintide and tirzepatide sit on different sides of the modern obesity-drug landscape. Cagrilintide is an investigational amylin analogue in Phase 3 development, while tirzepatide is an FDA-approved GIP/GLP-1 dual agonist with large regulatory-grade clinical programs.
Metabolic & Weight Loss
Investigational
Phase 3 investigational
Long-acting amylin analogue / amylin-receptor agonist.
Cagrilintide now has meaningful Phase 3 human evidence, but monotherapy and the CagriSema fixed-dose combination are separate development programs and should not be treated as interchangeable.
Open cagrilintide guide & calculator →Metabolic & Weight Loss
FDA-approved
Regulatory-grade / large Phase 3
Dual GIP and GLP-1 receptor agonist.
A dual-incretin therapy with regulatory-grade evidence and a useful comparator for both semaglutide and investigational retatrutide.
Open Tirzepatide guide →Save this comparison
Keep the current two- or three-compound comparison for quick access in My Tools.
Loading comparison tool...
Regulatory status and evidence level are separate ideas. A compound can have meaningful human research and still remain investigational, while an FDA-approved product can have approval only for specific indications and formulations.
BACToBasics also separates direct human intervention evidence from animal, cell, endogenous-biology, or related-molecule evidence so weaker evidence does not inherit the certainty of stronger research.
This page is generated from the same structured evidence records as the main interactive compare tool. Updating a compound's regulatory status, evidence summary, safety context, or source list updates both experiences rather than maintaining separate copies.
Read the Research & Editorial Policy →Evidence behind the comparison
These deep links are generated from the compounds in this comparison, so research and development pages stay connected as the underlying datasets grow.
Keep comparing
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
BACToBasics provides educational information only. Comparison pages are not medical advice, dosing advice, treatment guidance, anti-doping advice, or recommendations to use any compound.